Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BRITISH BIO-TECHNOLOGY GROUP's COLLAGENASE INHIBITOR ADJUNCTIVE

Executive Summary

BRITISH BIO-TECHNOLOGY GROUP's COLLAGENASE INHIBITOR ADJUNCTIVE treatment for metastases of breast cancer is projected to move into Phase I/II clinical trials "toward the end of 1990," according to the company's CEO Keith McCullagh. The British Bio-technology exec told a Nov. 28 conference sponsored by Robertson Stephens that the firm is developing an injectable collagenase inhibitor as an adjunctive therapy in preventing metastases of breast cancer from attacking surrounding bone. Collagenase inhibitors are designed to block the human protein responsible for bone and cartilage destruction in rheumatoid and ostoearthritis. British Bio-technology's lead collagenase inhibitor compound, BB 94, has shown activity in animal models, McCullagh said. The collagenase inhibitor agents are being developed for arthritis indications by SmithKline Beecham under the licensing and R&D collaboration between the two firms forged earlier this year ("The Pink Sheet" March 20, T&G-3). The collaborative development project for a second generation TPA between British Bio-technology and SmithKline is apparently in limbo until the beginning of next year. McCullagh said that SmithKline Beecham is currently considering the future of the "second generation thrombolytic entity that has an increased activity over TPA [and] has a prolonged half-life" as a "potential development candidate as a back-up to Eminase." The restructuring of SmithKline and Beecham has delayed a final decision on the second generation product. "We expect," McCullagh said, "to be in the position to have a fair idea of the product plans for that by next January." The Oxford, England firm could then plan for the initiation of Phase I trials. British Bio-technology and SmithKline Beckman entered into a collaborative R&D program in mid-1987 for the development of thrombolytic products based on recombinant DNA and gene synthesis techniques ("The Pink Sheet" May 18, 1987, T&G-5). Under the agreement, SmithKline has responsibility for developing "new patentable compounds" resulting from the research and, in return, will receive exclusive worldwide marketing rights. British Bio-technology will receive royalties from any product sales. British Bio-technology was established in 1986. The private company completed its third round of financing in June, raising $ 35 mil., and is currently planning to enter Phase I clinical trials next year with an AIDS vaccine in addition to the collagenase inhibitor for breast cancer. Besides SmithKline Beecham, the firm also has collaborative agreements with J&J's McNeil Consumer Products for the development of an HMG-CoA reductase cholesterol-lowering agent and with Pfizer on the role of endothelial cells in vascular disease.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel